Revive Therapeutics (RVV) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free RVV Stock Alerts C$0.08 +0.01 (+14.29%) (As of 07/22/2019) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVIDtmcnet.com - April 23 at 8:07 AMRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Productmarkets.businessinsider.com - April 18 at 8:03 AMRevive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDfinanznachrichten.de - March 27 at 4:23 PMRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDfinance.yahoo.com - March 27 at 10:10 AMRevive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDfinanznachrichten.de - March 19 at 11:42 AMRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDmarkets.businessinsider.com - March 19 at 11:42 AMRevive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Updatefinanznachrichten.de - March 12 at 8:23 AMRevive Therapeutics Provides Corporate Updatefinancialpost.com - March 12 at 7:08 AMRevive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110markets.businessinsider.com - February 26 at 8:53 PMRevive Therapeutics Explores the Use of Bucillamine for Long COVIDmarkets.businessinsider.com - February 1 at 9:20 AMRevive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500markets.businessinsider.com - January 31 at 7:29 PMRevive Therapeutics Ltd. Announces Offering of Up to $3 Millionfinancialpost.com - January 24 at 7:03 PMRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canadatmcnet.com - January 16 at 8:29 AMRevive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillaminefinanznachrichten.de - January 10 at 2:05 PMRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillaminemarkets.businessinsider.com - January 10 at 9:05 AMTravere Therapeutics expects Q4 net product sales from continuing operations to be about $40Mmsn.com - January 8 at 4:03 PMRevive Therapeutics Announces Results of Annual General and Special Meeting of Shareholdersmarkets.businessinsider.com - December 20 at 5:50 PMRevive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillaminemarkets.businessinsider.com - December 18 at 8:03 AMRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillaminefinancialpost.com - December 18 at 7:07 AMRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposuremarkets.businessinsider.com - October 17 at 4:48 PMRevive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposuremarkets.businessinsider.com - October 17 at 11:47 AMRevive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Developmentfinanznachrichten.de - October 11 at 2:48 PMRevive Therapeutics Provides Update of Novel Bucillamine Formulation Developmenttmcnet.com - October 11 at 9:47 AMItaly turns to Kyrgyz shepherds to revive Sardinian farmingft.com - September 28 at 9:58 AMRevive Therapeutics Ltd.: Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Developmentfinanznachrichten.de - August 22 at 9:11 AMRevive Therapeutics Announces Initiation of Novel Bucillamine Formulation Developmentstockhouse.com - August 22 at 9:11 AMNJ volunteer firefighter helps revive man who collapsed during basketball gamecbsnews.com - August 21 at 7:41 AMRevive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agentsstockhouse.com - July 28 at 11:29 AMRVV.CN - Revive Therapeutics Ltd.finance.yahoo.com - July 11 at 6:42 PMRevive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19stockhouse.com - July 6 at 8:20 AMHow to Revive an Old Computer for Your Kid—or Decide on a New Onenytimes.com - July 3 at 10:47 PMRevive Therapeutics staying the course on Phase 3 trial of Bucillamine in Covid-19 patients after meeting with FDAproactiveinvestors.com - May 30 at 10:17 AMRevive Therapeutics halts Bucillamine for COVID-19 study; seeks data evaluation to inform next stepsproactiveinvestors.com - May 12 at 10:40 AMRevive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19benzinga.com - May 2 at 10:46 AMRevive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trialproactiveinvestors.com - May 2 at 10:46 AMRevive Therapeutics to review next steps for Phase 3 Bucillamine study in COVID-19 patientsproactiveinvestors.com - April 19 at 12:57 PMRevive Therapeutics spikes after update on oral COVID-19 drugmsn.com - April 19 at 12:57 PMRevive Therapeutics to review next steps for COVID-19 studyproactiveinvestors.com - April 19 at 12:57 PMRevive Therapeutics Ltd.: Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorderfinanznachrichten.de - March 28 at 10:15 AMRevive Therapeutics enrols first patient in psilocybin clinical study for methamphetamine use disorderproactiveinvestors.com - March 28 at 10:15 AMHowes: Why repealing right-to-work won't revive Michigan's good ol' daysdetroitnews.com - March 22 at 10:14 AMRevive Therapeutics Ltd.: Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19finanznachrichten.de - March 20 at 2:44 PMRevive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19financialpost.com - March 20 at 9:44 AMRevive Therapeutics provides update of Phase 3 clinical study for Bucillamine in treatment of COVID-19proactiveinvestors.com - March 20 at 9:44 AMNorth Dakota's top court will not revive state's abortion banreuters.com - March 19 at 12:40 AMScientists revive ancient ‘zombie viruses’ from Siberian permafrost that can infect amoeba cellsfoxnews.com - March 16 at 2:16 AMRevive Therapeutics reveals positive update on FDA meeting for Bucillamine study in treatment of COVID-19proactiveinvestors.com - March 8 at 11:05 AMWill Iraq Finally Revive This Mothballed Megaproject?oilprice.com - February 23 at 6:33 PMColombia and Venezuela sign deal to revive tradenews.yahoo.com - February 22 at 12:12 AMRevive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Developmentfinance.yahoo.com - February 6 at 1:27 PM Get Revive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVV and its competitors with MarketBeat's FREE daily newsletter. Email Address Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> RVV Media Mentions By Week RVV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVV News Sentiment▼1.030.41▲Average Medical News Sentiment RVV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVV Articles This Week▼10▲RVV Articles Average Week Get Revive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: QPT News IOT News HEM News SVS News IMV News AEZS News RVX News ATE News KNE News SBM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:RVV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revive Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
